A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period.

Timeline

Start

2026-06

Primary completion

2027-09

Completion

2027-12

Drugs

Indications